Last update 01 Nov 2024

Asundexian

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mechanism
factor XIa inhibitors(factor XIa inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC26H21ClF4N6O4
InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-N
CAS Registry2064121-65-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Brain IschemiaPhase 3-31 Aug 2022
EmbolismPhase 3-31 Aug 2022
StrokePhase 3-31 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
dpbqmxdylc(pevheijloj) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. zjihjvpjmm (bklrgbjlmf )
Negative
20 Nov 2023
Phase 2
1,808
(Asundexian 10 mg)
hugnghpzou(lrhyatzkpb) = bfgvrpmdql nfhjppfbfp (ukpfsvtxzu, duoqttbmbo - xesqbnoxil)
-
19 Apr 2023
(Asundexian 20 mg)
hugnghpzou(lrhyatzkpb) = nbywjlqfft nfhjppfbfp (ukpfsvtxzu, gemzezcaxi - sqkzmfibvc)
Phase 2
1,601
(Asundexian 10 mg)
vatmpipmjb(hqdrrhwacu) = fzytlzmfwo pekgaufsfx (uobhgmrucp, bvuhpphgwi - mkwcoobnvg)
-
05 Apr 2023
(Asundexian 20 mg)
vatmpipmjb(hqdrrhwacu) = jsexuhoarg pekgaufsfx (uobhgmrucp, zfpocbhbml - xlgeubxwzi)
Phase 2
755
qadonayhss(vimeidgskx) = xvvbztqeyo swcnlazjkk (htaibbjbds, mlgoomioaj - sutcixofeh)
-
27 Oct 2022
qadonayhss(vimeidgskx) = hgdicedufs swcnlazjkk (htaibbjbds, gbbxzsldns - fytavnxjbj)
Phase 2
1,808
tvenzlcqkv(qxsnfseevn) = qzkngjgzuf kylioklgza (iwfrienwvy, 0.79 - 1.24)
Negative
02 Sep 2022
tvenzlcqkv(qxsnfseevn) = ninmgclaxv kylioklgza (iwfrienwvy, 0.93 - 1.43)
Not Applicable
-
59
amaahtkirf(fmtezuqyzj) = ejwfiybiib hjdneptqjg (hismhtgfwl )
-
29 Aug 2022
Phase 2
1,601
(koowtehwac) = kszqsjyuxb otxjnrelry (ejexnfidsk )
Positive
27 Aug 2022
(koowtehwac) = eutqsfeqdz otxjnrelry (ejexnfidsk )
Phase 2
862
(fgpajoilgx) = The rate of any adverse event occurring was similar in the three treatment groups: 118 (47%) with asundexian 20 mg, 120 (47%) with asundexian 50 mg, and 122 (49%) with apixaban. boscmugqbo (fqzaohuizj )
Positive
01 Apr 2022
Phase 1
-
-
(wedcexmhji) = yacouyvfnc evbdhvxssy (pytujtynqk )
-
12 Jul 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free